Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: Results of a Phase 2a study

Transplant International

Volumn 27, Issue 1, 2014, Pages 77-86

  Stoelben, Susanne ^a   Arns, Wolfgang ^b   Renders, Lutz ^c   Hummel, Jürgen ^d   Mühlfeld, Anja ^e   Stangl, Manfred ^c   Fischereder, Michael ^f   Gwinner, Wilfried ^g   Suwelack, Barbara ^h   Witzke, Oliver ⁱ   Dürr, Michael ^j   Beelen, Dietrich W ⁱ   Michel, Detlef ^k   Lischka, Peter ^a   Zimmermann, Holger ^a   Rübsamen Schaeff, Helga ^a   Budde, Klemens ^j  

^a AiCuris GmbH   (Germany)

^b Transplantationszentrum Kliniken der Stadt K oln   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Fleming House   (United Kingdom)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f Campus Grosshadern   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

AIC246; human cytomegalovirus; kidney transplantation; letermovir; preemptive therapy

Indexed keywords

GANCICLOVIR; LETERMOVIR; PLACEBO; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GENE DOSAGE; GRAFT RECIPIENT; HEALTH CARE QUALITY; HUMAN; HUMAN CYTOMEGALOVIRUS; KIDNEY GRAFT; LABORATORY TEST; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION;

AIC246; HUMAN CYTOMEGALOVIRUS; KIDNEY TRANSPLANTATION; LETERMOVIR; PREEMPTIVE THERAPY;

ACETATES; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; QUINAZOLINES; VIRAL LOAD; VIREMIA;

EID: 84896497988     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12225     Document Type: Article

References (26)

1. Kotton CN,. CMV: prevention, Diagnosis and therapy. Am J Transplant 2013; 13 (Suppl 3): 24.
2. Griffiths PD, Walter S,. Cytomegalovirus. Curr Opin Infect Dis 2005; 18: 241.
3. Gandhi MK, Khanna R,. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725.
4. Sampathkumar P, Paya C,. Pathogenesis in transplant recipients. In:, Emery VC, ed. Human Cytomegalovirus. London, UK: International Medical Press, 2007: 7: 1.
5. Eid AJ, Razonable RR,. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965.
6. Lowance D, Neumayer HH, Legendre CM, et al,. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
7. Lischka P, Zimmermann H,. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008; 8: 541.
8. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
9. Kasiske BL, Zeier MG, Craig JC, et al,. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): 1.
10. Andrei G, De CE, Snoeck R,. Drug targets in cytomegalovirus infection. Infect Disord Drug Targets 2009; 9: 201.
11. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR,. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22: 162.
12. Reefschlaeger J, Bender W, Hallenberger S, et al,. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001; 48: 757.
13. Krosky PM, Underwood MR, Turk SR, et al,. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol 1998; 72: 4721.
14. Lischka P, Hewlett G, Wunberg T, et al,. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54: 1290.
15. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P,. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884.
16. Kaul DR, Stoelben S, Cober E, et al,. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11: 1079.
17. Marschall M, Stamminger T, Urban A, et al,. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (Letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012; 56: 1135.
18. Kropeit D, McCormick D, VonRichter O, et al,. Phase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246. Abstr 1994, 50th Intersci Conf Antimicrob Agents Chemother (ICAAC). Boston, MA 2010.
19. Sassenscheidt J, Rohayem J, Illmer T, Bandt D,. Detection of beta-herpesviruses in allogenic stem cell recipients by quantitative real-time PCR. J Virol Methods 2006; 138: 40.
20. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al,. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89.
21. Humar A, Siegal D, Moussa G, Kumar D,. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005; 192: 1154.
22. Kimberlin DW, Acosta EP, Sanchez PJ, et al,. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008; 197: 836.
23. Hebart H, Lengerke C, Ljungman P, et al,. Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT. Bone Marrow Transplant 2010; 46: 408.
24. Kotton CN,. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 2010; 6: 711.
25. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D,. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009; 10: 191.
26. Lurain NS, Chou S,. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689.